The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1482
November 23, 2015
View Complete Issue         Table of Contents 2019 
Cobicistat (Tybost) and Combinations for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cobicistat (Tybost) and Combinations for HIV
November 23, 2015 (Issue: 1482)
Cobicistat, a pharmacokinetic enhancer that boosts levels of some HIV drugs but has no antiretroviral activity of its own, is now available alone as Tybost (Gilead) and in fixed-dose combinations with the protease inhibitors atazanavir (Evotaz...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cobicistat (Tybost) and Combinations for HIV
Article code: 1482c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.